Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Joint Design of Transmit Waveforms for Object Tracking in Coexisting Multimodal Sensing Systems.

Kota JS, Papandreou-Suppappola A.

Sensors (Basel). 2019 Apr 12;19(8). pii: E1753. doi: 10.3390/s19081753.

2.

A Systematic Review of miR-29 in Cancer.

Kwon JJ, Factora TD, Dey S, Kota J.

Mol Ther Oncolytics. 2018 Dec 31;12:173-194. doi: 10.1016/j.omto.2018.12.011. eCollection 2019 Mar 29. Review.

3.

Lower expression of tumor microRNA-26a is associated with higher recurrence in patients with hepatocellular carcinoma undergoing surgical treatment.

Jones KR, Nabinger SC, Lee S, Sahu SS, Althouse S, Saxena R, Johnson MS, Chalasani N, Gawrieh S, Kota J.

J Surg Oncol. 2018 Sep;118(3):431-439. doi: 10.1002/jso.25156. Epub 2018 Aug 4.

PMID:
30076741
4.

Safety and Efficacy of AAV Retrograde Pancreatic Ductal Gene Delivery in Normal and Pancreatic Cancer Mice.

Quirin KA, Kwon JJ, Alioufi A, Factora T, Temm CJ, Jacobsen M, Sandusky GE, Shontz K, Chicoine LG, Clark KR, Mendell JT, Korc M, Kota J.

Mol Ther Methods Clin Dev. 2017 Sep 30;8:8-20. doi: 10.1016/j.omtm.2017.09.006. eCollection 2018 Mar 16.

5.

EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming.

Adelaiye-Ogala R, Budka J, Damayanti NP, Arrington J, Ferris M, Hsu CC, Chintala S, Orillion A, Miles KM, Shen L, Elbanna M, Ciamporcero E, Arisa S, Pettazzoni P, Draetta GF, Seshadri M, Hancock B, Radovich M, Kota J, Buck M, Keilhack H, McCarthy BP, Persohn SA, Territo PR, Zang Y, Irudayaraj J, Tao WA, Hollenhorst P, Pili R.

Cancer Res. 2017 Dec 1;77(23):6651-6666. doi: 10.1158/0008-5472.CAN-17-0899. Epub 2017 Oct 4.

6.

Bioavailability of Lumefantrine Is Significantly Enhanced with a Novel Formulation Approach, an Outcome from a Randomized, Open-Label Pharmacokinetic Study in Healthy Volunteers.

Jain JP, Leong FJ, Chen L, Kalluri S, Koradia V, Stein DS, Wolf MC, Sunkara G, Kota J.

Antimicrob Agents Chemother. 2017 Aug 24;61(9). pii: e00868-17. doi: 10.1128/AAC.00868-17. Print 2017 Sep.

7.

Pancreatic cancer: Stroma and its current and emerging targeted therapies.

Kota J, Hancock J, Kwon J, Korc M.

Cancer Lett. 2017 Apr 10;391:38-49. doi: 10.1016/j.canlet.2016.12.035. Epub 2017 Jan 14. Review.

PMID:
28093284
8.

Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.

Kwon JJ, Willy JA, Quirin KA, Wek RC, Korc M, Yin XM, Kota J.

Oncotarget. 2016 Nov 1;7(44):71635-71650. doi: 10.18632/oncotarget.11928.

9.

Gene targets of mouse miR-709: regulation of distinct pools.

Surendran S, Jideonwo VN, Merchun C, Ahn M, Murray J, Ryan J, Dunn KW, Kota J, Morral N.

Sci Rep. 2016 Jan 8;6:18958. doi: 10.1038/srep18958.

10.

Evaluation of cytochrome P450 inductions by anti-epileptic drug oxcarbazepine, 10-hydroxyoxcarbazepine, and carbamazepine using human hepatocytes and HepaRG cells.

Sugiyama I, Murayama N, Kuroki A, Kota J, Iwano S, Yamazaki H, Hirota T.

Xenobiotica. 2016 Sep;46(9):765-74. doi: 10.3109/00498254.2015.1118774. Epub 2015 Dec 29.

PMID:
26711482
11.

Pathophysiological role of microRNA-29 in pancreatic cancer stroma.

Kwon JJ, Nabinger SC, Vega Z, Sahu SS, Alluri RK, Abdul-Sater Z, Yu Z, Gore J, Nalepa G, Saxena R, Korc M, Kota J.

Sci Rep. 2015 Jun 22;5:11450. doi: 10.1038/srep11450.

12.

Eteplirsen for the treatment of Duchenne muscular dystrophy.

Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, Alfano L, Gomez AM, Lewis S, Kota J, Malik V, Shontz K, Walker CM, Flanigan KM, Corridore M, Kean JR, Allen HD, Shilling C, Melia KR, Sazani P, Saoud JB, Kaye EM; Eteplirsen Study Group.

Ann Neurol. 2013 Nov;74(5):637-47. doi: 10.1002/ana.23982. Epub 2013 Sep 10.

13.

Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microrna dysregulation.

Rosales XQ, Malik V, Sneh A, Chen L, Lewis S, Kota J, Gastier-Foster JM, Astbury C, Pyatt R, Reshmi S, Rodino-Klapac LR, Clark KR, Mendell JR, Sahenk Z.

Muscle Nerve. 2013 May;47(5):731-9. doi: 10.1002/mus.23669. Epub 2013 Mar 29.

14.

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Hsu SH, Wang B, Kota J, Yu J, Costinean S, Kutay H, Yu L, Bai S, La Perle K, Chivukula RR, Mao H, Wei M, Clark KR, Mendell JR, Caligiuri MA, Jacob ST, Mendell JT, Ghoshal K.

J Clin Invest. 2012 Aug;122(8):2871-83. doi: 10.1172/JCI63539. Epub 2012 Jul 23.

15.

Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D.

Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Taylor LE, Flanigan KM, Gastier-Foster JM, Astbury C, Kota J, Sahenk Z, Walker CM, Clark KR.

Ann Neurol. 2010 Nov;68(5):629-38. doi: 10.1002/ana.22251.

16.

Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy.

Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, Al-Dahhak R, Lewis S, Shilling CJ, Kota J, Serrano-Munuera C, Hayes J, Mahan JD, Campbell KJ, Banwell B, Dasouki M, Watts V, Sivakumar K, Bien-Willner R, Flanigan KM, Sahenk Z, Barohn RJ, Walker CM, Mendell JR.

Ann Neurol. 2010 Jun;67(6):771-80. doi: 10.1002/ana.22024.

PMID:
20517938
17.

Follistatin gene delivery enhances muscle growth and strength in nonhuman primates.

Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, Tucker D, Shilling CJ, Therlfall WR, Walker CM, Weisbrode SE, Janssen PM, Clark KR, Sahenk Z, Mendell JR, Kaspar BK.

Sci Transl Med. 2009 Nov 11;1(6):6ra15. doi: 10.1126/scitranslmed.3000112.

18.

Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins.

Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, Craenen JM, Lewis S, Malik V, Shilling C, Byrne BJ, Conlon T, Campbell KJ, Bremer WG, Viollet L, Walker CM, Sahenk Z, Clark KR.

Ann Neurol. 2009 Sep;66(3):290-7. doi: 10.1002/ana.21732.

19.

PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats.

Kaminskas LM, Kota J, McLeod VM, Kelly BD, Karellas P, Porter CJ.

J Control Release. 2009 Dec 3;140(2):108-16. doi: 10.1016/j.jconrel.2009.08.005. Epub 2009 Aug 15.

PMID:
19686787
20.

Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model.

Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT.

Cell. 2009 Jun 12;137(6):1005-17. doi: 10.1016/j.cell.2009.04.021.

21.

Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.

Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR.

Muscle Nerve. 2009 Mar;39(3):283-96. doi: 10.1002/mus.21244. Review.

22.

Aberrant signal transduction pathways in myeloproliferative neoplasms.

Kota J, Caceres N, Constantinescu SN.

Leukemia. 2008 Oct;22(10):1828-40. doi: 10.1038/leu.2008.236. Epub 2008 Sep 4. Review.

PMID:
18769448
23.

Assessing the issue of instability due to Michael adduct formation in novel chemical entities possessing a carbon-carbon double bond during early drug development--applicability of common laboratory analytical protocols.

Polepally AR, Kumar VV, Bhamidipati R, Kota J, Naveed SA, Reddy KH, Mamidi RN, Selvakumar N, Mullangi R, Srinivas NR.

Biomed Chromatogr. 2008 Sep;22(9):960-76. doi: 10.1002/bmc.1015.

PMID:
18683847
24.

Lymphatic absorption of subcutaneously administered proteins: influence of different injection sites on the absorption of darbepoetin alfa using a sheep model.

Kota J, Machavaram KK, McLennan DN, Edwards GA, Porter CJ, Charman SA.

Drug Metab Dispos. 2007 Dec;35(12):2211-7. Epub 2007 Sep 17.

PMID:
17875672
25.

Membrane chaperone Shr3 assists in folding amino acid permeases preventing precocious ERAD.

Kota J, Gilstring CF, Ljungdahl PO.

J Cell Biol. 2007 Feb 26;176(5):617-28.

26.

Ssh4, Rcr2 and Rcr1 affect plasma membrane transporter activity in Saccharomyces cerevisiae.

Kota J, Melin-Larsson M, Ljungdahl PO, Forsberg H.

Genetics. 2007 Apr;175(4):1681-94. Epub 2007 Feb 7.

27.

Specialized membrane-localized chaperones prevent aggregation of polytopic proteins in the ER.

Kota J, Ljungdahl PO.

J Cell Biol. 2005 Jan 3;168(1):79-88. Epub 2004 Dec 28.

28.

Quantitative determination of ragaglitazar in rat plasma by HPLC: validation and application in pharmacokinetic study.

Kota J, Mullangi R, Mamidi RN, Rajagopalan R.

Biomed Chromatogr. 2002 Dec;16(8):495-9.

PMID:
12474210
29.

Pharmacological and pharmacokinetic evaluation of celecoxib prodrugs in rats.

Mamidi RN, Mullangi R, Kota J, Bhamidipati R, Khan AA, Katneni K, Datla S, Singh SK, Rao KY, Rao CS, Srinivas NR, Rajagopalan R.

Biopharm Drug Dispos. 2002 Oct;23(7):273-82.

PMID:
12355578
30.

Corotating variations of cosmic rays near the South heliospheric pole.

Kota J, Jokipii JR.

Science. 1995 May 19;268(5213):1024-5.

PMID:
17774229
31.

[Acute myocardial infarct associated with early perforation of the septum].

KOTA J.

Orv Hetil. 1963 Feb 3;104:225-6. Hungarian. No abstract available.

PMID:
14035059

Supplemental Content

Support Center